Compugen Ltd. announced on January 8, 2025, that the first patient was dosed in a Phase 1 clinical trial for COM503, now known as GS-0321. This potential first-in-class antibody targets IL-18 binding protein and is licensed to Gilead, with Compugen responsible for conducting the Phase 1 trial.
The multi-center dose escalation and dose expansion trial will assess the safety, tolerability, and pharmacokinetics of GS-0321 as a monotherapy and in combination with Gilead's anti-PD1, zimberelimab, in patients with advanced solid tumors. The trial's initiation in the fourth quarter of 2024 proceeded as planned.
This milestone follows Gilead's $60 million upfront payment and a $30 million IND clearance milestone to Compugen. Compugen remains eligible for up to an additional $758 million in future development, regulatory, and commercial milestone payments, along with tiered royalties on worldwide net sales, highlighting the significant financial potential of this partnership.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.